The Shanghai and Shenzhen Exchange strictly inspected the IPO of nuclear acid detection enterprises, and the Saint Bio became the first nucleic acid detection company in China.
According to the Southern Metropolis Daily, the Shanghai Stock Exchange Science and Technology Board Disclosure Disclosure Science and Technology Board of the Municipal Committee of the Municipal Party Committee The 98th Review Conference announced in 2022, pointing out that there are still related matters in the Sacred Biology that need to be further verified, soCancellation of the company's listing application.In response to the relevant situation, the media sent an interview email to check the Biosheng Biology on Monday (November 28). As of the press press, the other party did not respond further.
Reporting pointed out that although the nuclear -related acid detection business enterprises of the "tie" queuing IPO this year are mostly "selling watermen" (that is, providing equipment, consumables, etc. for third -party nucleic acid detection agencies), it still causes regulatory supervisionAttention of the department.Earlier, the Shanghai Stock Exchange and the Shenzhen Stock Exchange almost synchronized in an interview with the media: For enterprise IPOs involving nucleic acid testing business, the associations of related businesses and main business of nucleic acid testing and the sustainability of related income will be focused on.
Public information shows that the Saint -Saint Biology is mainly engaged in the R & D, production and sales of molecular, protein and cell biological reagents. In a strict sense, the Shengsheng creature is the raw material supplier of the nucleic acid detection agencyFirst, the main products related to nucleic acid detection test agents are mainly provided.
Although it claims that "the relevant income of nucleic acid detection has less relying on", in recent years, the proportion of related businesses in Shengsheng has increased, which may become one of the important factors for its IPO to be suspended.
The Prospects of Shengsheng Biological (Draft) shows that from 2020 to the first half of 2022, the company's sales revenue related to crown diseases was 46.1476 million yuan (RMB, the same below, about 886.8, about 886.810,000 yuan), 81.7413 million yuan and 76.897 million yuan, accounting for 24.77%, 25.42%, and 38.28%of the current operating income, respectively.
It is understood that "sustainable business ability" is an important point for regulatory departments to strictly review the IPO of nucleic acid testing enterprises.
In the previous inquiry, the regulatory authorities needed to ask the Saint Biology to explain whether the crown disease -related business was sustainable and whether the company had the risk of a significant decline in performance.In this regard, the Shengsheng creatures frankly said in the response and prospectus (draft) that with the optimization and adjustment of the epidemic prevention policy, the demand for the detection of nucleic acid detection in the terminal market will continue to decrease, and the competitiveness of the detection of the raw material market will increase. "The company's coronal disease -related business may face the risk of reduced sales and reduced profit space. "
In fact, the nucleic acid detection related businesses of the Shengsheng creatures have fallen sharply in unit prices.The prospectus shows that the average unit price of the crown disease -related products of the Shengsheng creatures is 0.58 yuan /rxn, 0.46 yuan/RXN, and 0.14 yuan/RXN, respectively.
In the second half of this year, the price of products related to crown diseases further declined. In the third quarter of this year, the average sales unit price of related products was only 0.10 yuan/RXN.If combined with related sales income, the raw materials of the crown disease detection of Yisheng creatures have entered the stage of "price blogging", which may also be the performance pressure of some crown disease testing companies.
In addition, in addition to the sustainability of the crown disease business, the accounts receivable of the Shengsheng creatures have increased rapidly.From 2020 to June 2022, the accounts receivable of Yisheng creatures were 45.8129 million yuan, 73.9403 million yuan, and 127 million yuan. Among them, the receivables receivable in the first half of this year were far higher than the net profit of 32.1455 million yuan in the same period.The prospectus shows that 97%of the accounts receivables of the Shengsheng creatures are within one year. Based on the top five customers in their ranking, the top four customers in the accounts receivable basically include nucleic acid testing business.
